Rafinlar 75mg Capsule

Rafinlar 75mg Capsule contains dabrafenib 75mg, a prescription targeted anticancer medicine belonging to the BRAF inhibitor class. It is used for selected cancers carrying specific BRAF V600 mutations, including unresectable or metastatic melanoma and, in combination with trametinib, certain BRAF V600 mutation-positive non-small cell lung cancers and other approved indications depending on the market.

Rafinlar is marketed by Novartis and is available as 50mg and 75mg hard capsules. The 75mg capsule contains dabrafenib equivalent to 75mg of the active drug.

Dabrafenib is a molecularly targeted therapy that inhibits abnormal BRAF signaling involved in cancer-cell growth. Because treatment is dependent on the tumor's molecular characteristics, appropriate BRAF mutation testing is required before treatment.

Product Information

Brand Name

Rafinlar®

Generic Name

Dabrafenib

Active Ingredient

Dabrafenib mesylate equivalent to dabrafenib 75mg

Drug Class

BRAF Kinase Inhibitor

Therapeutic Class

Targeted Anticancer Therapy

Strength

75mg

Dosage Form

Hard Capsule

Route

Oral

Indication

BRAF V600 mutation-positive cancers according to applicable regulatory approval

Primary Oncology Use

BRAF V600 mutation-positive unresectable or metastatic melanoma

Combination Therapy

Frequently used with trametinib for applicable indications

Prescription

Yes

Typical Pack Size

28 Capsules

Manufacturer/Brand

Novartis / market dependent

What Is Rafinlar 75mg Capsule?

Rafinlar 75mg is an oral targeted cancer medicine containing dabrafenib. Rather than broadly suppressing rapidly dividing cells, dabrafenib specifically targets abnormal signaling associated with mutated BRAF proteins.

Rafinlar 75mg is particularly relevant for patients whose tumors have an eligible BRAF V600 mutation, which should be confirmed using an appropriate diagnostic test before treatment.

Rafinlar 75mg and BRAF V600 Mutation

Rafinlar is a biomarker-driven cancer treatment. It is not appropriate for every patient with melanoma or lung cancer.

Before treatment, the tumor generally needs to be tested for the relevant BRAF V600 mutation using an appropriate validated diagnostic method.

This makes the following commercial search relationship particularly important:

Rafinlar 75mg → Dabrafenib 75mg → BRAF Inhibitor → BRAF V600 Mutation Treatment → Targeted Cancer Therapy

Rafinlar 75mg with Trametinib

Dabrafenib is commonly combined with trametinib for several approved BRAF V600 mutation-positive cancers.

The combination targets two different points in the MAPK pathway: dabrafenib inhibits BRAF, while trametinib inhibits MEK. This dual pathway inhibition can provide greater suppression of abnormal MAPK signaling than BRAF inhibition alone in applicable cancers.

The combination should only be prescribed and monitored by an oncology specialist.

Generic Rafinlar 75mg / Dabrafenib 75mg

The active pharmaceutical ingredient in Rafinlar is dabrafenib.

Where an authorized generic or equivalent dabrafenib product is available, commercially relevant searches may include:

Generic Rafinlar 75mg, Dabrafenib 75mg, Dabrafenib 75mg Capsule, Generic Dabrafenib 75mg, Dabrafenib Alternative, Rafinlar Alternative

The term generic Rafinlar should only be used when the specific product has the appropriate generic/equivalent regulatory status in the target market.

Availability & Ordering

Rafinlar 75mg is a prescription oncology medicine and should be obtained through an appropriately licensed pharmacy or authorized pharmaceutical supplier.

Commercial searches include Rafinlar 75mg Capsule, Dabrafenib 75mg, Buy Rafinlar 75mg, Buy Dabrafenib 75mg, Rafinlar 75mg Price, Dabrafenib 75mg Price, Generic Rafinlar 75mg, Dabrafenib 75mg Supplier and related terms.

Availability, prescription requirements, importation and dispensing regulations differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

How it works

Dabrafenib selectively inhibits BRAF kinase, including forms of the BRAF protein containing activating V600 mutations.

BRAF is part of the MAPK signaling pathway, which regulates cellular growth and proliferation. In tumors containing an activating BRAF mutation, this pathway can become abnormally active and contribute to uncontrolled cancer-cell growth.

By inhibiting mutant BRAF signaling, dabrafenib can reduce downstream signaling and help slow the growth and proliferation of eligible cancer cells.

Rafinlar/dabrafenib is used for specific cancers with qualifying BRAF mutations. Depending on the approved indication and country, uses include:

• BRAF V600 mutation-positive unresectable or metastatic melanoma
• BRAF V600 mutation-positive non-small cell lung cancer (NSCLC) in combination with trametinib
• Certain other BRAF V600 mutation-positive tumors where the combination of dabrafenib and trametinib is approved

The exact approved indications differ between regulatory jurisdictions, so treatment should follow the local prescribing information.

The dose and treatment schedule must be determined by the treating oncologist according to the patient's cancer type, mutation status, treatment combination, medical history and response to therapy.

Rafinlar capsules should be taken exactly as prescribed. The capsules should be swallowed whole and should not be opened, crushed or chewed.

Do not change the dose or stop treatment without consulting the prescribing oncologist.

Rafinlar 75mg Storage

Follow the storage conditions stated on the product packaging and official prescribing information. Keep the capsules in their original container and out of reach of children.

Do not use capsules beyond the expiry date.

Dabrafenib can cause adverse effects, and the risk profile can vary depending on whether it is used alone or together with trametinib.

Potential adverse effects include:

• Fever
• Fatigue
• Nausea
• Headache
• Joint pain
• Skin reactions
• Diarrhea
• Vomiting
• Decreased appetite

More serious reactions can occur, including severe fever-related reactions, eye problems, bleeding, heart-related effects, liver abnormalities and development of new skin cancers. Patients should promptly report concerning symptoms to their oncology team.